Literature DB >> 2742248

Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV).

J Berenguer1, S Moreno, E Cercenado, J C Bernaldo de Quirós, A García de la Fuente, E Bouza.   

Abstract

In an 8-month period nine patients with human immunodeficiency virus (HIV) infection were diagnosed as having visceral leishmaniasis; all diagnoses were based on cultures (eight from bone marrow and one from the skin). Visceral leishmaniasis developed before full-blown acquired immunodeficiency syndrome (AIDS) in seven patients and at the same time as or after AIDS in the other two patients. Three patients had a history of leishmaniasis. Clinical manifestations and laboratory findings were atypical. Leishmania species were cultured from samples taken from all patients; however, six patients had an insignificant antileishmanial antibody titer and Leishmania amastigotes were not seen in their bone marrow smears. Four isolates were identified by isoenzyme analysis as Leishmania donovani infantum. Five patients died, including two patients who had completed at least one 3-week course of therapy with N-methylglucamine antimoniate. Screening should be done for visceral leishmaniasis in patients with HIV infection who live or travel in areas where the disease is endemic. The diagnosis of visceral leishmaniasis may frequently be missed if cultures are not done.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2742248     DOI: 10.7326/0003-4819-111-2-129

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

1.  The need for new therapeutic approaches in visceral leishmaniasis during HIV infection.

Authors:  A Lafeuillade; R Quilichini; C Dhiver; C Mary; J A Gastaut
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

2.  Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma.

Authors:  D E Wyatt; P V Coyle
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

3.  Visceral leishmaniasis in human immunodeficiency virus disease.

Authors:  C Montalban
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

4.  One patient, two unusual conditions and three basic lessons.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

5.  Pyrexia of undetermined origin in advanced HIV disease.

Authors:  C M Tang; C P Conlon; R F Miller
Journal:  Genitourin Med       Date:  1997-08

6.  Diagnosis of visceral leishmaniasis in HIV-infected patients.

Authors:  I Gasser; A Jaén; J González; E Ribera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

7.  Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment.

Authors:  S Fenske; H J Stellbrink; H Albrecht; H Greten
Journal:  Klin Wochenschr       Date:  1991-10-31

8.  Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania.

Authors:  M Chen; S B Christensen; J Blom; E Lemmich; L Nadelmann; K Fich; T G Theander; A Kharazmi
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain.

Authors:  J A Pineda; J A Gallardo; J Macías; J Delgado; C Regordán; F Morillas; F Relimpio; J Martín-Sánchez; A Sánchez-Quijano; M Leal; E Lissen
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral Leishmaniasis in immunocompromised patients.

Authors:  R Piarroux; F Gambarelli; H Dumon; M Fontes; S Dunan; C Mary; B Toga; M Quilici
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.